Cargando…
Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection
COVID-19 pandemic represented a challenge in the management of treatments for Multiple Sclerosis (MS), such as Natalizumab (NTZ). NTZ interferes with the homing of lymphocytes into the central nervous system, reducing immune surveillance against opportunistic infection. Although NTZ efficacy starts...
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542399/ https://www.ncbi.nlm.nih.gov/pubmed/35158454 http://dx.doi.org/10.1016/j.msard.2021.103345 |
| _version_ | 1784589422495268864 |
|---|---|
| author | Landi, Doriana Cola, Gaia Mantero, Vittorio Balgera, Roberto Moiola, Lucia Nozzolillo, Agostino Dattola, Vincenzo Sinisi, Leonardo Fantozzi, Roberta Di Lemme, Sonia Centonze, Diego Mataluni, Giorgia Nicoletti, Carolina Gabri Marfia, Girolama Alessandra |
| author_facet | Landi, Doriana Cola, Gaia Mantero, Vittorio Balgera, Roberto Moiola, Lucia Nozzolillo, Agostino Dattola, Vincenzo Sinisi, Leonardo Fantozzi, Roberta Di Lemme, Sonia Centonze, Diego Mataluni, Giorgia Nicoletti, Carolina Gabri Marfia, Girolama Alessandra |
| author_sort | Landi, Doriana |
| collection | PubMed |
| description | COVID-19 pandemic represented a challenge in the management of treatments for Multiple Sclerosis (MS), such as Natalizumab (NTZ). NTZ interferes with the homing of lymphocytes into the central nervous system, reducing immune surveillance against opportunistic infection. Although NTZ efficacy starts to decline 8 weeks after the last infusion, increasing the risk of disease reactivation, evidence is lacking on the safety of reinfusion during active SARS-CoV-2 infection. We report clinical outcomes of 18 pwMS receiving NTZ retreatment during confirmed SARS-CoV-2 infection. No worsening of infection or recovery delay was observed. Our data supports the safety of NTZ redosing in these circumstances. |
| format | Online Article Text |
| id | pubmed-8542399 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85423992021-10-25 Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection Landi, Doriana Cola, Gaia Mantero, Vittorio Balgera, Roberto Moiola, Lucia Nozzolillo, Agostino Dattola, Vincenzo Sinisi, Leonardo Fantozzi, Roberta Di Lemme, Sonia Centonze, Diego Mataluni, Giorgia Nicoletti, Carolina Gabri Marfia, Girolama Alessandra Mult Scler Relat Disord Article COVID-19 pandemic represented a challenge in the management of treatments for Multiple Sclerosis (MS), such as Natalizumab (NTZ). NTZ interferes with the homing of lymphocytes into the central nervous system, reducing immune surveillance against opportunistic infection. Although NTZ efficacy starts to decline 8 weeks after the last infusion, increasing the risk of disease reactivation, evidence is lacking on the safety of reinfusion during active SARS-CoV-2 infection. We report clinical outcomes of 18 pwMS receiving NTZ retreatment during confirmed SARS-CoV-2 infection. No worsening of infection or recovery delay was observed. Our data supports the safety of NTZ redosing in these circumstances. Published by Elsevier B.V. 2022-01 2021-10-24 /pmc/articles/PMC8542399/ /pubmed/35158454 http://dx.doi.org/10.1016/j.msard.2021.103345 Text en © 2021 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Landi, Doriana Cola, Gaia Mantero, Vittorio Balgera, Roberto Moiola, Lucia Nozzolillo, Agostino Dattola, Vincenzo Sinisi, Leonardo Fantozzi, Roberta Di Lemme, Sonia Centonze, Diego Mataluni, Giorgia Nicoletti, Carolina Gabri Marfia, Girolama Alessandra Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection |
| title | Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection |
| title_full | Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection |
| title_fullStr | Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection |
| title_full_unstemmed | Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection |
| title_short | Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection |
| title_sort | safety of natalizumab infusion in multiple sclerosis patients during active sars-cov-2 infection |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542399/ https://www.ncbi.nlm.nih.gov/pubmed/35158454 http://dx.doi.org/10.1016/j.msard.2021.103345 |
| work_keys_str_mv | AT landidoriana safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT colagaia safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT manterovittorio safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT balgeraroberto safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT moiolalucia safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT nozzolilloagostino safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT dattolavincenzo safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT sinisileonardo safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT fantozziroberta safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT dilemmesonia safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT centonzediego safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT matalunigiorgia safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT nicoletticarolinagabri safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection AT marfiagirolamaalessandra safetyofnatalizumabinfusioninmultiplesclerosispatientsduringactivesarscov2infection |